as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹3,202.5
Change
-29.3 (-0.91%)
Open
₹3,245.0
Prev. Close
₹3,231.8
Day High
₹3,245.0
Day Low
₹3,190.8
Volume Analysis
Traded
9,501
Delivered
5,466
Delivery %
57.53%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (47.1%)
- •Strong operating margin (24.0%)
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,288.94 | ₹3,266.97 | ₹3,234.74 | ₹3,212.77 | ₹3,180.54 | ₹3,158.57 | ₹3,126.34 |
| Fibonacci | ₹3,266.97 | ₹3,246.27 | ₹3,233.47 | ₹3,212.77 | ₹3,192.07 | ₹3,179.27 | ₹3,158.57 |
| Camarilla | ₹3,217.41 | ₹3,212.44 | ₹3,207.47 | ₹3,212.77 | ₹3,197.53 | ₹3,192.56 | ₹3,187.6 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-21.85%
1 Week
-2.39%
1 Month
+13.27%
3 Months
-4.48%
6 Months
+1.24%
1 Year
-29.91%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹1,506.86
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
44.54%
Net margin 20.52% × asset turnover 1.34x × equity multiplier 1.62x
Company Overview
Sector
Healthcare
Market Cap
₹7,375 Cr
P/E (TTM)
16.7
ROE
47.1%
Book Value
₹374.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 20 Nov 2026. Not investment advice.
TopFund Analysis
Sanofi India Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 57/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (47.1%); strong operating margin (24.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
57/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company's working capital requirements have reduced from 27.6 days to 20.4 days
- −Stock is trading at 8.56 times its book value
- −Debtor days have increased from 32.9 to 41.7 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Bengaluru GST show cause notice dropped; Sanofi India pays Rs.17,680 tax and interest on 16 November 2026.
Sanofi India declared Rs 75 interim dividend for FY2026; record date 5 November 2026.
Sanofi India reported Q3 FY2026 results and declared ₹75 interim dividend; record date is 5 November 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales + | 515 | 491 | 469 | 511 | 464 | 524 | 515 |
| Expenses + | 393 | 377 | 370 | 374 | 348 | 404 | 397 |
| Operating Profit | 122 | 114 | 100 | 137 | 116 | 120 | 118 |
| OPM % | 24.0% | 23.0% | 21.0% | 27.0% | 25.0% | 23.0% | 23.0% |
| Other Income + | 57 | 82 | 77 | 41 | 21 | 2 | 14 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 |
| Profit before tax | 169 | 186 | 167 | 169 | 127 | 113 | 122 |
| Tax % | 27.0% | 18.0% | 18.0% | 19.0% | 19.0% | 27.0% | 25.0% |
| Net Profit + | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS in Rs | 53 | 66 | 60 | 59 | 45 | 36 | 40 |
| Raw PDF | — | — | — | — | — | — | — |
| YoY Sales growth | — | — | — | — | -10 | 7 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 1,996 | 2,013 |
| Expenses + | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 1,508 | 1,522 |
| Operating Profit | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 488 | 491 |
| OPM % | 17.0% | 17.0% | 23.0% | 22.0% | 23.0% | 22.0% | 25.0% | 26.0% | 25.0% | 24.0% | 24.0% |
| Other Income + | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 317 | 78 |
| Interest | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 36 | 37 |
| Profit before tax | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 767 | 531 |
| Tax % | 29.0% | 33.0% | 37.0% | 37.0% | 38.0% | 31.0% | 29.0% | 25.0% | 28.0% | 21.0% | 22.0% |
| Net Profit + | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 413 |
| EPS in Rs | 115 | 140 | 132 | 142 | 165 | 180 | 208 | 411 | 270 | 262 | 180 |
| Dividend Payout % | 39.0% | 46.0% | 51.0% | 50.0% | 51.0% | 194.0% | 176.0% | 119.0% | 211.0% | 64.0% | 65.0% |
| Sales growth | 9 | 11 | 8 | 4 | 13 | 11 | -5 | 2 | -6 | — | 1 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 |
| Other Liabilities + | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 |
| Total Liabilities | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 |
| Fixed Assets + | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 |
| CWIP | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,384 | 1,281 |
| Total Assets | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 |
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Dec 2014 (S) | Dec 2015 (S) | Dec 2016 (S) | Dec 2017 (S) | Dec 2018 (S) | Dec 2019 (S) | Dec 2020 (S) | Dec 2021 (S) | Dec 2022 (S) | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | 399 | 230 | 462 |
| Cash from Investing Activity + | 61 | 36 | -155 | -79 | -73 | 66 | 276 | 631 | 651 | 38 | -180 |
| Cash from Financing Activity + | -122 | -147 | -180 | -188 | -197 | -183 | -810 | -849 | -1,583 | -878 | -392 |
| Net Cash Flow | 205 | 102 | -13 | 168 | 104 | 295 | 78 | 341 | -533 | -610 | -111 |
| Free Cash Flow | 247 | 184 | 253 | 379 | 317 | 337 | 810 | 574 | 412 | 220 | 426 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 114 | 93 | 101 | 118 | 99 | 96 | 112 | 111 | 94 | 97 | 114 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 10.78% | 10.61% | 11.21% | 11.2% | 11.04% | 11.01% | 10.94% | 11.75% | 12.75% | 12.84% | 14.05% | 14.46% |
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% |
| FII | 6.31% | 6.11% | 5.81% | 5.78% | 5.64% | 5.58% | 5.61% | 5.57% | 5.55% | 5.65% | 5.69% | 5.73% |
| DII | 22.51% | 22.88% | 22.6% | 22.62% | 22.94% | 23.02% | 23.06% | 22.28% | 21.3% | 21.12% | 19.87% | 19.4% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sanofi India Limited (this stock) | 7,375 | 16.7 | 8.56 | 47.1% |
| Kovai Medical Center & Ho | 7,108 | 123.0 | 24.58 | 22.2% |
| Bliss Gvs Pharma Ltd | 7,075 | 43.5 | 5.5 | 11.8% |
| Suven Life Sciences Ltd | 7,850 | — | 17.38 | -81.5% |
| Thyrocare Tech Ltd | 7,940 | 45.3 | 14.31 | 28.4% |
| Sun Pharma Adv.res.co.ltd | 6,680 | 4.05 | 4.64 | 279.0% |
| Nephrocare Health Serv L | 6,500 | 50.8 | 5.46 | 8.83% |
Which Mutual Funds Hold Sanofi India Limited?
Frequently Asked Questions about Sanofi India Limited
Sanofi India Limited (SANOFI) closed at ₹3,202.5 on NSE on 19 November 2026, down 29.3 (0.91%) from the previous close.
Sanofi India Limited trades on the NSE (National Stock Exchange of India) under the symbol SANOFI.
Sanofi India Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 16.7.
Sanofi India Limited has a dividend yield of 2.34%.
Sanofi India Limited's 52-week high is ₹4,638.0 and its 52-week low is ₹2,758.0.
Sanofi India Limited has a market capitalisation of ₹7,375 crore.
Sanofi India Limited has a TopFund Quality Score of 57/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sanofi India Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.